Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Research & Development (2022 - 2026)

Axsome Therapeutics' Research & Development history spans 5 years, with the latest figure at $52.7 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 17.62% to $52.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $145.0 million, a 25.66% decrease, with the full-year FY2025 number at $183.3 million, down 2.03% from a year prior.
  • Research & Development hit $52.7 million in Q1 2026 for Axsome Therapeutics, up from $2.6 million in the prior quarter.
  • Over the last five years, Research & Development for AXSM hit a ceiling of $55.0 million in Q4 2024 and a floor of $2.6 million in Q4 2025.
  • Historically, Research & Development has averaged $31.3 million across 5 years, with a median of $30.8 million in 2023.
  • Biggest five-year swings in Research & Development: soared 142.23% in 2024 and later plummeted 95.27% in 2025.
  • Tracing AXSM's Research & Development over 5 years: stood at $14.7 million in 2022, then surged by 109.64% to $30.8 million in 2023, then surged by 78.57% to $55.0 million in 2024, then plummeted by 95.27% to $2.6 million in 2025, then soared by 1926.04% to $52.7 million in 2026.
  • Business Quant data shows Research & Development for AXSM at $52.7 million in Q1 2026, $2.6 million in Q4 2025, and $40.2 million in Q3 2025.